Total liabilities · 2023–2025
Genmab total liabilities
$7.0B+450.2% · FY2025
Genmab (GMAB) reported $7.0B in total liabilities for fiscal 2025, +450.2% year on year.
Total liabilities — Total liabilities is everything the company owes at the balance-sheet date — debt, payables, deferred revenue and provisions together. Where a filer does not tag it, we calculate it as total assets minus total equity and label the figure as calculated.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2023–2025 compound annual growth +259.1%
Figures are reported under IFRS, in US dollars.
Total liabilities at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Genmab total liabilities |url=https://companiesranked.com/en/company/genmab/total-liabilities |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Genmab total liabilities. CompaniesRanked. https://companiesranked.com/en/company/genmab/total-liabilitiesBibTeX
@misc{companiesranked-en-company-genmab-total-liabilities-2026,
author = {{CompaniesRanked}},
title = {{Genmab total liabilities}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/genmab/total-liabilities}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001434265-26-000014 · February 17, 2026
{{cite web |title=Genmab total liabilities — 20-F (0001434265-26-000014) |url=https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231_d2.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.